Once A Wildfire Issue, Why Has The Push To Ban Lasix Cooled????

This week’s LET IT RIDE.COM HOT TOPIC comes from Steven Crist of The Daily Racing Form…take a read and VOICE AN OPINION!

Five reasons why the effort to ban Lasix has stalled

The movement to ban Lasix from American racing, which looked like an odds-on favorite only a year ago, seems to have pulled up at the top of the stretch with the announcement last week that the Breeders’ Cup has scrapped its plan to enforce a ban in this year’s races.

Lasix will again be banned in only the four juvenile races while the treatment will be permitted in the 10 others, and insiders expect even the juvenile ban to be gone in another year or two. So, if there are 30,000 races in North America in 2013, Lasix will be permitted in 29,996 of them and prohibited in just four.

Regardless of which side of the thorny and divisive debate you are on, this is a stunning reversal. A year ago, Kentucky regulators were on the verge of phasing out Lasix completely but now are likelier to phase in a retreat from those rules. Efforts to enact similar legislation stalled in New York and never got off the ground in California. Numerous industry organizations have retreated from strong anti-Lasix stances.

What happened? Zealots on each side of the issue will call it a triumph of good or evil by forces of enlightenment or darkness, but it may be more valuable to examine why a movement that seemed inevitable suddenly lost its momentum. There probably are dozens of other factors, but here are five that contributed to the sputter:

◗ The willful attempt to blur the clear lines between administering a legal and regulated medication and the nefarious use of illegal and dangerous drugs to fix the outcome of races was a tactical error that alienated potential supporters who have an open mind on the topic.

Proponents of a ban consistently overstated their case and lost hearts and minds by trying to make Lasix sound inherently dangerous and linking its usage – with little veterinary evidence or support – to a supposed decline in the health and durability of the breed.

◗ The claim by proponents of a ban that Lasix use was harming the sport’s popularity was unfounded and unconvincing. After more than two decades of widespread Lasix usage, a span in which the sport had periods of both growth and decline, the argument that it had suddenly begun alienating potential customers lacked credibility. This was borne out when in 2012, a year in which racing probably received an unprecedented amount of negative coverage for medication and animal-welfare issues, American betting handle actually increased for the first time in six years.

◗ The lack of support for a Lasix ban from virtually any successful trainer left the anti-Lasix proponents not only without an influential spokesman but also with the weak and nasty rebuttal that trainers are either incompetent or shady. Even trainers who ban proponents thought shared their views said they found Lasix a useful and humane treatment.

◗ While it may be intellectually defensible (through the “playing by the existing rules” and “level playing field” arguments) to rail against the use of Lasix while continuing to race one’s own horses on it, people both inside and outside the industry found this to be a mixed message at best. Telling people to do what you say, not what you do, never goes over well in general and took the wind from the sails of the position that Lasix was so detrimental to racing that it must be banned.

◗ The argument that the United States is out of step with the rest of the world by uniquely permitting Lasix is both true and sobering, but a lack of conformity is not in and of itself a reason to change. What was needed to make that a more compelling argument was some illustration of how the United States could implement foreign procedures to replace Lasix instead of an assumption that we must be wrong.

There also continues to be a lot of misinformation surrounding comparisons between American and, in particular, European racing. It has become gospel that horses in Europe make more starts per year than American runners, and that Lasix might be to blame, when, in fact, the statistics are almost identical.

Whatever the reasons, the impetus to change Lasix policy has evaporated, but that should not mean the topic is permanently closed. Even those who have come to accept and defend its use would be hard-pressed to argue that it is commendable that American racing has gone down a path where virtually every horse is treated with it. Perhaps the next time the issue rears its head – and it will – there can be a more constructive, civilized, and informed discussion.